#biotechupdate
biotechupdate
259 views
3 ກຳລັງສົນທະນາ
ມາແຮງ
ຫຼ້າສຸດ
·
--
ສັນຍານກະທິງ
Allogene Therapeutics ($ALLO ) is making big moves in biotech! 🧬
Trading around $1.68 - $1.70,$ALLO is drawing strong interest as analysts maintain a "Strong Buy" consensus with aggressive long-term price targets.
Why is $ALLO on the radar?
Pipeline Progress: Key cancer programs like cema-cel received FDA Fast Track and RMAT designations, boosting confidence in its novel CAR-T therapies.
Solid Financial Runway: A lower-than-expected Q2 loss and strong cash management extend their operations comfortably into 2029.
Upcoming Catalysts: Traders are watching for clinical data updates on their autoimmune program (ALLO-329) later this year.
What’s Next?
While the stock remains in a low valuation zone near $1.68, steady clinical results could spark a quick trend reversal. Watch out for short-term market volatility ahead of upcoming pipeline readouts!
#ALLO #BiotechUpdate #stockmarketnews #CancerResearch #WallStreet
{spot}(ALLOUSDT)
Allogene Therapeutics ($ALLO ) is making big moves in biotech! 🧬
Trading around $1.68 - $1.70,$ALLO is drawing strong interest as analysts maintain a "Strong Buy" consensus with aggressive long-term price targets.
Why is $ALLO on the radar?
Pipeline Progress: Key cancer programs like cema-cel received FDA Fast Track and RMAT designations, boosting confidence in its novel CAR-T therapies.
Solid Financial Runway: A lower-than-expected Q2 loss and strong cash management extend their operations comfortably into 2029.
Upcoming Catalysts: Traders are watching for clinical data updates on their autoimmune program (ALLO-329) later this year.
What’s Next?
While the stock remains in a low valuation zone near $1.68, steady clinical results could spark a quick trend reversal. Watch out for short-term market volatility ahead of upcoming pipeline readouts!
#ALLO #BiotechUpdate #stockmarketnews #CancerResearch #WallStreet
Trading around $1.68 - $1.70,$ALLO is drawing strong interest as analysts maintain a "Strong Buy" consensus with aggressive long-term price targets.
Why is $ALLO on the radar?
Pipeline Progress: Key cancer programs like cema-cel received FDA Fast Track and RMAT designations, boosting confidence in its novel CAR-T therapies.
Solid Financial Runway: A lower-than-expected Q2 loss and strong cash management extend their operations comfortably into 2029.
Upcoming Catalysts: Traders are watching for clinical data updates on their autoimmune program (ALLO-329) later this year.
What’s Next?
While the stock remains in a low valuation zone near $1.68, steady clinical results could spark a quick trend reversal. Watch out for short-term market volatility ahead of upcoming pipeline readouts!
#ALLO #BiotechUpdate #stockmarketnews #CancerResearch #WallStreet
43
ເຂົ້າສູ່ລະບົບເພື່ອສຳຫຼວດເນື້ອຫາເພີ່ມເຕີມ
ເຂົ້າຮ່ວມກຸ່ມຜູ້ໃຊ້ຄຣິບໂຕທົ່ວໂລກໃນ Binance Square.
⚡️ ໄດ້ຮັບຂໍ້ມູນຫຼ້າສຸດ ແລະ ທີ່ມີປະໂຫຍດກ່ຽວກັບຄຣິບໂຕ.
💬 ໄດ້ຮັບຄວາມໄວ້ວາງໃຈຈາກຕະຫຼາດແລກປ່ຽນຄຣິບໂຕທີ່ໃຫຍ່ທີ່ສຸດໃນໂລກ.
👍 ຄົ້ນຫາຂໍ້ມູນເຊີງເລິກທີ່ແທ້ຈາກນັກສ້າງທີ່ໄດ້ຮັບການຢືນຢັນ.
ອີເມວ / ເບີໂທລະສັບ
ຫົວຂໍ້ທີ່ກໍາລັງນິຍົມ
1
#AnthropicIPOProspectusCouldValueItOver$2T
36 views
20 ກຳລັງສົນທະນາ
2
#HackersDrainOver12.4MXRPFromDCENTWallets
339 views
35 ກຳລັງສົນທະນາ
3
#SECSaysDecentralizedTokenBuybacksNotInvestmentContracts
1 views
1 ກຳລັງສົນທະນາ
4
#UKFCAWinsCourtOrderToRecover851400Pounds
50,583 views
962 ກຳລັງສົນທະນາ
5
#ChainlinkLaunchesCCIP2WithEnterpriseVerification
60,742 views
1,103 ກຳລັງສົນທະນາ
6
#GoldFallsTo$4144
20,602 views
175 ກຳລັງສົນທະນາ
7
#QNTFallsOver40%FromMorningHigh
109,614 views
1,482 ກຳລັງສົນທະນາ
8
#USDTAdds845900HoldersInPast7Days
28,879 views
535 ກຳລັງສົນທະນາ
9
#KospiFalls2.7%SamsungSKHynixDropOver5%
40,733 views
661 ກຳລັງສົນທະນາ
10
#BitgetCEOConfirms$388MStolenInHack
6,006 views
45 ກຳລັງສົນທະນາ